Prime Medicine (PRME) Depreciation & Amortization (CF) (2021 - 2026)

Prime Medicine's Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 9.18% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (up 14.8% YoY) and the FY2025 annual result came in at $7.3 million, up 19.47% from the prior year.
• Depreciation & Amortization (CF) was $1.9 million for Q1 2026 at Prime Medicine, down from $1.9 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.9 million in Q3 2025 and bottomed at $293000.0 in Q1 2022.
• A 5-year average of $1.3 million and a median of $1.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 279.91% — and 2026, when it advanced 9.18%.
• Prime Medicine's Depreciation & Amortization (CF) stood at $870000.0 in 2022, then jumped by 43.33% to $1.2 million in 2023, then soared by 37.69% to $1.7 million in 2024, then advanced by 9.26% to $1.9 million in 2025, then retreated by 1.07% to $1.9 million in 2026.
• Business Quant data shows PRME's Depreciation & Amortization (CF) at $1.9 million in Q1 2026, $1.9 million in Q4 2025, and $1.9 million in Q3 2025.